An interventional study of Targeted next-generation sequencing in Drug-resistant Tuberculosis, HIV Coinfection and Cost-Benefit Analysis, sponsored by University of California, San Francisco. Recruiting at 1 site in South Africa. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa — 7 open to participants now, 8 under way, 3 of them phase 3. Tuberculosis, Multidrug-Resistant · South Africa.
Among the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, this one is the 4th largest by planned enrollment of the 37 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 40th registered.
132 studies on the registry are indexed under Tuberculosis, Multidrug-Resistant; 25 are open to participants now.
Browse Tuberculosis, Multidrug-Resistant studies →7 of the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa are open now. Recruiting first, the newest first:
Albert Einstein College of Medicine · Sites in South Africa
Ages 18+
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in South Africa, China, Georgia and 7 more countries
Ages 14+
Johns Hopkins University · Sites in South Africa
Ages 18+
Columbia University · Sites in South Africa
Ages 18+ · Healthy volunteers
Seoul National University Hospital · Sites in South Africa
Ages 15+
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 16 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 194 across 88 interventional studies indexed under Tuberculosis, Multidrug-Resistant.
Median enrollment 248 across the 37 interventional studies, 786 across the 9 observational. Of the 32 that completed or were terminated, 17 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 46 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 2 studies filed under Tuberculosis, Multidrug-Resistant — fewer than ten, so there is no comparison to draw.
2 of the studies in Tuberculosis, Multidrug-Resistant with a site in South Africa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05553236University of California, San FranciscoPragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis | 2027-01 |
| NCT05633056Columbia UniversityAn Adaptive Randomized Controlled Trial | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In addition, participants later found to have isolates with rifamycin susceptibility on at least two additional tests (e.g., phenotypic DST, LPA, or sequencing) will be considered late exclusions.
Batched targeted deep sequencing in addition to the locally accepted standard of care drug susceptibility determination of multidrug/extensively drug-resistant tuberculosis (M/XDR-TB)
Diagnostic Test: Targeted next-generation sequencing
Locally accepted standard of care which is consistent with the WHO recommendations for the drug susceptibility determination of M/XDR-TB
During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee.
Number of participants with prespecified end of treatment outcomes
The number of participants with each of the following prespecified end of treatment outcomes will be reported: cure, treatment completed, loss to follow up, treatment failure, death, transfer, and still on treatment.
Time frame: At the anticipated completion of prescribed treatment, up to 18 months
12-month relapse-free survival
Length of time after treatment ends that the patient survives without TB recurrence
Time frame: From completion of prescribed treatment to death or TB recurrence, up to 12 months
Exposure time to ineffective drugs
Cumulative length of time on individual drugs to which Mtb is found to be resistant, per participant
Time frame: At the anticipated completion of prescribed treatment, up to 18 months
Number of participants with acquired drug resistance
Number of participants with M.tuberculosis acquiring additional drug resistance during treatment
Time frame: At the anticipated completion of prescribed treatment, up to 18 months
Time to effective treatment initiation with three drugs
Length of time from diagnosis to treatment initiation with at least three effective drugs to which M.tuberculosis is susceptible
Time frame: From diagnosis to treatment initiation with at least three effective drugs, up to 18 months
Time to effective treatment initiation with four drugs
Length of time from diagnosis to treatment initiation with at least four effective drugs to which M.tuberculosis is susceptible
Time frame: From diagnosis to treatment initiation with at least four effective drugs, up to 18 months
Time to culture conversion
Length of time from diagnosis to stable culture conversion, defined as the first of two (consecutive or non-consecutive) negative sputum cultures without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs of active TB, up to 9 months
Time frame: From diagnosis to stable culture conversion, up to 9 months
Number of participants with clinical uptake of sequencing intervention results
The number of sequencing intervention results with treatment regimen adjustment where appropriate treatment change is indicated
Time frame: At the anticipated completion of prescribed treatment, up to 18 months
Cost-effectiveness of the sequencing intervention
Costs of necessary personnel, consumables, facility, logistics, and per unit tests
Time frame: At the anticipated completion of prescribed treatment, up to 18 months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Jan 2027, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tuberculosis, Multidrug-Resistant →
University of California, San Francisco →